Moderna (MRNA) Q2 2026 Earnings Call Transcript

Moderna reported Q2 2026 revenue of $145M (+2% y/y) and a net loss of $782M (EPS loss $1.97), while lowering 2026 guidance: cost of sales to $1.7B (-$0.1B) and R&D to $2.9B (-$0.1B). Cash and investments fell to $6.9B from $7.5B, and the company paid a $950M litigation settlement in July. Despite the financial drag, management reaffirmed up to 10% 2026 revenue growth, supported by international government partnerships (69% of first-half revenue) and upcoming key regulatory milestones including an Aug. 5 PDUFA for mRNA-1010 flu vaccine.

Analysis

The important issue is not whether Moderna can still win approvals; it is whether the company can convert a growing list of shots on goal into durable, repeatable cash flow before the market loses patience. The 2026 framework implies only modest revenue leverage against a still-large fixed cost base, so every incremental commercial miss on U.S. seasonal demand or rollout slippage in Europe matters disproportionately. The near-term winners are the contract manufacturing / public procurement channels that can absorb more of Moderna’s output; the losers are incumbent respiratory players that rely on slower-moving strain cycles and less flexible manufacturing.

Norovirus now looks less like a binary failure than a timing reset, but the second-order effect is that it delays proof that Moderna can build an accepted franchise outside respiratory disease. That matters because the equity story is increasingly a multi-year pipeline narrative, and any slip pushes investors back to valuing the name on cash burn and launch execution rather than on platform optionality. The oncology program is the real upside lever: if INT shows durable efficacy in broader tumors, the stock can re-rate hard; if the interim does not stop for efficacy, the market may initially read that as a soft miss even though the final analysis could still be economically meaningful.

Contrarian view: the consensus may be too focused on the next readout and underweight the structural benefit of a faster strain-update platform plus international commercialization. But the bear case is still stronger on a 6-12 month horizon: until a second or third recurring revenue stream is visible, every rally risks being sold as a financing-free biotech story with a shrinking COVID base and event-driven volatility.

Key Decisions for Investors

• Tactically avoid chasing MRNA into the Aug. 5 PDUFA; use any pre-decision strength to trim or hedge with short-dated calls, because the stock is still trading as a binary event name and the base business remains seasonal.
• If FDA review stays constructive into the PDUFA window, buy a small Sep/Oct MRNA call spread for a 2-3x payoff profile; invalidate on a CRL, label narrowing, or any indication the launch timing slips beyond fall season.
• Set a hard alert for the INT interim press release: if the study stops for efficacy, add to MRNA on the thesis that oncology becomes a second valuation pillar; if it merely continues, treat it as a hold-only event until final analysis.
• Keep norovirus on watch rather than trading it now; any further enrollment or endpoint delay should be treated as a 2027 revenue deferral and a reason to lower long-duration expectations.
• For relative-value, consider MRNA vs. broad biotech exposure only on approval-driven spikes; the stock still appears more expensive on future optionality than on near-term recurring earnings.